A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

Stopped early · Phase 1

Conditions studied: Multiple Myeloma

In brief

This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.

Key facts

Study ID

NCT02954796

Run by

Seagen Inc.

People needed

27

Starts

2016-12-01

Expected to finish

2019-07-17

Last updated by the study team

2019-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG] ).
• Age 18 years or older.
• An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
• Life expectancy greater than 3 months.
• Received at least 2 prior lines of therapy for MM including an immunomodulatory drug and a proteasome inhibitor.
• Measurable disease, as defined by at least one of the following: Serum M protein 0.5 g/dL or higher, Urine M protein 200 mg/24 hr or higher, Serum free light chain (SFLC) 10 mg/dL or higher, and Abnormal SFLC ratio.
• Adequate hematologic, renal, and hepatic function
• A negative pregnancy test (for females of childbearing potential).
• Patients must provide written informed consent.

You may not qualify if…

• Other invasive malignancy within the past 3 years.
• Active cerebral/meningeal disease related to the underlying malignancy.
• Active Grade 3 or higher infection.
• Known to be positive for HIV or known to have active hepatitis B or C.
• Previous allogeneic stem cell transplant.
• Idiopathic interstitial pneumonia or impaired diffusion capacity of the lung for carbon monoxide (DLCO).
• Cerebrovascular or cardiovascular event, or congestive heart failure within the last 6 months.
• Females who are pregnant or breastfeeding.

Where it is running

• Mayo Clinic Arizona — Scottsdale, Arizona, United States
• City of Hope National Medical Center — Duarte, California, United States
• Winship Cancer Institute / Emory University School of Medicine — Atlanta, Georgia, United States
• Holden Comprehensive Cancer Center / University of Iowa — Iowa City, Iowa, United States
• Karmanos Cancer Institute / Wayne State University — Detroit, Michigan, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Weill Cornell Medical College — New York, New York, United States
• Charles A. Sammons Cancer Center / Baylor University Medical Center — Dallas, Texas, United States
• Swedish Cancer Institute — Seattle, Washington, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.